This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
aml
AML
Clonal myeloid malignancy; key drivers: FLT3-ITD/TKD (~30%), NPM1 (~30%), DNMT3A (~20%), IDH1/2 (~20%), and KMT2A rearrangements. Venetoclax+azacitidine is frontline for unfit patients; midostaurin (FLT3) and enasidenib/ivosidenib (IDH2/1) are approved targeted therapies.
Entry Metadata
| Field | Value |
|---|---|
| ID | aml |
| Name | AML |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617-629. · PubMed 32786187
- Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454-464. · PubMed 28644114
- Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722-731. · PubMed 28588020